Kali-Extracts has launched a dedicated website for its cannabis-based therapy candidate, RespRX, for chronic obstructive pulmonary disease (COPD) and related disorders.
The company announced that as it moves toward the goal of federal approval of RespRX, its website will be updated regularly with information about the applications’ status, as well as ongoing RespRX investigations and developments, KALY stated in a press release.
This follows the company’s recent filing of an U.S. patent and brand name trademark applications for RespRX specifically for treating COPD symptoms and similar respiratory conditions.
Increasing evidence suggests that non-psychotropic cannabis-derived compounds, such as pharmaceutical grade cannabidiol (CBD), may hold clinically relevant effects that can help those affected by a wide range of illnesses.